Harvoni®, a fixed-dose combination of ledipasvir (an HCV NS5A inhibitor) and sofosbuvir (an HCV nucleotide analog NS5B polymerase inhibitor, has been recently approved by the FDA and is awaiting marketing authorisation in Europe. Interactions between ledipasvir/sofosbuvir and comedications have been added to the web, app and printed versions of the charts.
Pharmacokinetic information for ledipasvir can be found in the investigational drug fact sheet (accessed via the Interaction Charts drop down menu). A PK fact sheet will be prepared once a European Summary of Characteristics is available for the ledipasvir/sofosbuvir combination.
